HENN MATTHEW R (Chief Scientific Officer) sold 1.1% of their position (89.00 shares) of SERES THERAPEUTICS, INC. on the open market
Open‑market sale worth $753.83 — a minor trim. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 2/18/2026ACC: 0001193125-26-057153
Officer· Chief Scientific Officer
Since Feb 2019
-89.00
Net shares
Net seller
$753.83
Total sold
1
Open market trades
0B · 1S
4
Total transactions
239.00 acquired · 328.00 disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
+239.00
Price / share
—
Trade value
—
% of position
3.2%
2/15/2026
7.53K→7.77K
Common Stock
Direct
Shares
−89.00
Price / share
$8.47
Trade value
$753.83
% of position
1.1%
2/15/2026
7.77K→7.68K
Total
Net shares
+150.00
Net value
-$753.83
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 2/15/2026 | M · Option Exercise | +239.00 | — | — | 3.2% | 7.53K | 7.77K |
| Common Stock Direct | 2/15/2026 | S · Sale | −89.00 | $8.47 | $753.83 | 1.1% | 7.77K | 7.68K |
| Total | +150.00 | -$753.83 | ||||||
Derivative Transactions2
Restricted Stock Units
Direct
Converts to
Common Stock
141.00 shares
Shares
−141.00
Strike price
Held after
563.00
Exercisable
—
2/15/2026
Restricted Stock Units
Direct
Converts to
Common Stock
98.00 shares
Shares
−98.00
Strike price
Held after
780.00
Exercisable
—
2/15/2026
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Restricted Stock Units Direct | Common Stock141.00 shares | 2/15/2026 | M · Option Exercise | −141.00 | — | 563.00 | |
| Restricted Stock Units Direct | Common Stock98.00 shares | 2/15/2026 | M · Option Exercise | −98.00 | — | 780.00 |